|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0026088,
umls-concept:C0027358,
umls-concept:C0030685,
umls-concept:C0033371,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0087111,
umls-concept:C0282151,
umls-concept:C0391871,
umls-concept:C0441712,
umls-concept:C0680255,
umls-concept:C0878751,
umls-concept:C1283071,
umls-concept:C1314939,
umls-concept:C1963578
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2006-12-28
|
|
pubmed:abstractText |
During late pregnancy, the antiprogesterone mifepristone facilitates prolactin release. This effect is enhanced by administration of the opioid antagonist naloxone, suggesting an inhibitory-neuromodulatory role of the opioid system. Since hypothalamic dopamine (DA) is the main regulator of prolactin release, in this study we explored the role of DA on prolactin release induced by mifepristone and naloxone treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3,4-Dihydroxyphenylacetic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/3-hydroxybenzylhydrazine,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Hormone Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Hydrazines,
http://linkedlifedata.com/resource/pubmed/chemical/Mifepristone,
http://linkedlifedata.com/resource/pubmed/chemical/Naloxone,
http://linkedlifedata.com/resource/pubmed/chemical/Narcotic Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Prolactin,
http://linkedlifedata.com/resource/pubmed/chemical/Tyrosine 3-Monooxygenase
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0028-3835
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2006 S. Karger AG, Basel.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
84
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
58-67
|
|
pubmed:meshHeading |
pubmed-meshheading:17090971-3,4-Dihydroxyphenylacetic Acid,
pubmed-meshheading:17090971-Animals,
pubmed-meshheading:17090971-Dopamine,
pubmed-meshheading:17090971-Enzyme Inhibitors,
pubmed-meshheading:17090971-Female,
pubmed-meshheading:17090971-Gene Expression Regulation,
pubmed-meshheading:17090971-Gene Expression Regulation, Enzymologic,
pubmed-meshheading:17090971-Hormone Antagonists,
pubmed-meshheading:17090971-Hydrazines,
pubmed-meshheading:17090971-Hypothalamus,
pubmed-meshheading:17090971-Mifepristone,
pubmed-meshheading:17090971-Naloxone,
pubmed-meshheading:17090971-Narcotic Antagonists,
pubmed-meshheading:17090971-Pregnancy,
pubmed-meshheading:17090971-Pregnancy, Animal,
pubmed-meshheading:17090971-Prolactin,
pubmed-meshheading:17090971-Rats,
pubmed-meshheading:17090971-Rats, Wistar,
pubmed-meshheading:17090971-Tyrosine 3-Monooxygenase
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Dopaminergic mechanisms involved in prolactin release after mifepristone and naloxone treatment during late pregnancy in the rat.
|
|
pubmed:affiliation |
Laboratorio de Reproducción y Lactancia, IMBECU-CONICET, Mendoza, Argentina. msoaje@lab.cricyt.edu.ar
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
